Berlin, Germany, Mar 26, 2008 - (ABN Newswire) - Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
The Berlin-based biotechnology company MOLOGEN AG announced today, that a grant application to the 7th EU Framework Program has been reviewed with maximum possible score. The project to develop a prophylactic and therapeutic vaccination against visceral leishmaniasis, a severe and often fatal infectious disease, reached the ideal score following international scientific peer review. Such reviewing score will favour a negotiating position with the EU.
Under the auspices of London School of Hygiene & Tropical Medicine, in this project MOLOGEN will be collaborating with experts from Germany, India, Iran, Israel, Tunisia, UK and USA. MOLOGEN's role in the project would be to work on the optimization of the MIDGE®-based vaccine, produce the vaccine and conduct pre-clinical safety tests.
Leishmaniasis is among the key indications of MOLOGEN's development program for MIDGE®-based DNA vaccines. A MIDGE®-based DNA vaccine against leishmaniasis in companion animals is currently subject of an advanced clinical development program, conducted by an undisclosed worldwide leading animal health company.
About Leishmaniasis Parasites of the genus Leishmania, the pathogens causing the disease leishmaniasis, are transmitted by the bites of sandflies from animals to humans or among human beings. With high prevalence, leishmaniasis occurs in regions of subtropical and Mediterranean climate.
The World Health Organisation (WHO) has classified different forms of leishmaniasis as an emerging and neglected disease. To develop new and more effective therapeutics and prophylactic vaccines against leishmaniasis, a number of multi-national research programs has been launched.
About MOLOGEN MOLOGEN AG, a biopharmaceutical company based in Berlin, specializes in the research and development of innovative medicines based on DNA structures (DNA: deoxyribonucleic acid).
Its patented DNA-based technology platforms MIDGE® and dSLIM® form a universal foundation with a wide range of possible applications. Activities focus on product developments for the treatment of cancer and vaccines for serious infections in humans and animals.
MOLOGEN was founded in 1998 and was the first German biotechnology company to go public. MOLOGEN AG shares are listed in the General Standard of Deutsche Börse (ISIN DE 0006637200).
Disclaimer concerning prognoses Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.
MOLOGEN AG Fabeckstr. 30, 14195 Berlin, Germany Contact: Joerg Petrass Email: investor@mologen.com Phone: +49-30-84 17 88-13 Fax: +49-30-84 17 88-50
--- End of Message ---
MOLOGEN AG Fabeckstr. 30 Berlin Germany
WKN: 663720; ISIN: DE0006637200; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, General Standard in Frankfurter Wertpapierbörse, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;
Copyright © Hugin AS 2008. All rights reserved.
MOLOGEN AG
http://www.mologen.comISIN: DE0006637200
Stock Identifier: XFRA.MGN
